Background and Aims: Mucosal healing is associated with improved long-term clinical outcomes in patients with ulcerative colitis. This population-based study assessed endoscopic and histological mucosal healing within the first year of diagnosis. Methods: Consecutive patients diagnosed with ulcerative colitis from six countries in Asia were prospectively enrolled. Clinical demographics, blood markers and inflammatory activity were assessed at baseline. Mayo score and Nancy index were used to assess endoscopic and histological activities, respectively. Clinical, endoscopic and histological evaluations were repeated at 1 year. Logistic regression was performed to identify predictors of mucosal healing. Conclusions: Mucosal healing was achieved in fewer than half of patients with ulcerative colitis in the first year of diagnosis. An elevated ESR predicted less likelihood of endoscopic mucosal healing, while histological features of ulceration and being an ex-smoker at diagnosis predicted less likelihood of histological healing.
Introduction
Mucosal healing [MH] has emerged as an important treatment goal in patients with ulcerative colitis [UC] . Studies have shown that MH consistently predicted favourable outcomes, including sustained clinical remission, reduced hospitalization rates and fewer surgical resections. [1] [2] [3] [4] [5] In particular, complete MH when compared with partial MH was associated with higher rates of clinical remission, and the benefits of complete MH increased with follow-up time. 5 However, most data assessing MH in patients with UC have been limited to clinical trial settings and prospective population-based real-life data are scarce.
In a large Norwegian population-based study [IBSEN] that collected data between 1990 and 1994, 50% of incident UC patients achieved endoscopic MH in the first year of their diagnosis. Endoscopic MH predicted a decreased risk of colectomy but did not significantly predict favourable outcomes for other end points, including relapses, need for corticosteroids, complications and disease extension. Education of more than 12 years and extensive disease at diagnosis were predictors of MH. 4 Inflammatory bowel diseases [IBDs] have become a global disease with increasing incidence and prevalence in previously low-incidence areas including in Asia. 6, 7 We have previously reported that the crude overall annual incidence of UC per 100 000 people in Asia in 2011 was 1.37. 8 Despite largely similar early disease severity, evolution and clinical outcomes of UC, colectomy rates and overall total steroid exposures in newly diagnosed UC patients were lower in Asia compared with the West. 9 It was unclear whether the differences seen in Asian UC patients were related to milder disease at presentation, less disease progression or variations in disease management in Asia. 9 In the present study, we assessed MH and predictors of MH in UC patients in the first year of diagnosis, using data from a population-based inception cohort from six countries in Asia.
Materials and Methods

Study population
This population-based inception cohort consisted of incident cases from selected centres of The Asia-Pacific Crohn's and Colitis Epidemiology Study [ACCESS] group. The diagnostic criteria, period of inclusion, patient clinical demographics and ascertainment methods were standardized. 8 The present cohort of UC patients were diagnosed between January 2011 and December 2014 and living in pre-defined, well-described geographical areas from six regions or countries in Asia [China, Hong Kong, Indonesia, Macau, Singapore and Thailand]. The study was restricted to patients who were 15 years or older, and had a confirmed diagnosis of UC according to established clinical, endoscopic and histological criteria. Only patients who had been a resident in the defined study area at the time of diagnosis and had at least 6 months of follow-up data were included. Patients with an initial diagnosis of IBD-undetermined [IBD-U], and patients diagnosed at surgery were excluded.
Data collection
Patients were prospectively followed up every 3 months after diagnosis and throughout the study period. The patients were treated by each centre based on disease activity and severity. Follow-up colonoscopies were scheduled between visits at the discretion of the treating physician. Only patients who had received a baseline endoscopy and at least one complete endoscopic evaluation between 6 and 24 months after diagnosis were included. Endoscopic findings were also recorded to investigate the cumulative probabilities of having ever achieved endoscopic MH. Patients who had undergone proctocolectomy before the first follow-up colonoscopy were excluded.
At inclusion, data on clinical demographics, blood markers, and inflammatory activity based on endoscopic and histological findings were collected. Endoscopic evaluation was repeated at least once between 6 and 24 months for the assessment of MH. The need for steroids, hospitalization and surgical therapy, the development of cancer, and mortality were recorded [ Figure 1 ]. Data obtained at each follow-up visit were prospectively entered into the ACCESS database [http://www.access-apibd.com/index.html].
Clinical demographics including age, sex, smoking status, history of appendectomy, family history of IBD, disease extent and use of medications were collected. Disease extent was categorized using the Montreal classification 10 into proctitis, left-sided disease and extensive disease. Proctitis was defined as inflammation distal to the recto-sigmoid junction, left-sided disease was defined as inflammation distal to the splenic flexure and extensive disease was defined as inflammation proximal to the splenic flexure. Medications were broadly categorized into 5-aminosalicylates [5- 15 Histological MH was defined as a Nancy index of 0 or 1. Histological features including basal plasmacytosis, cryptitis, crypt abscess or ulceration were also recorded. Cohen's kappa coefficient was calculated to measure inter-rater agreement. If there was disagreement between the two researchers, a third researcher [SN] reviewed the reports to achieve a consensus among the three researchers.
The primary outcome was the proportion of patients who achieved endoscopic MH and histological MH, respectively. Secondary outcomes were predictors of MH, and impacts of MH on subsequent clinical course including need for steroids, hospitalization, surgery, cancer and mortality.
The study was conducted in compliance with the Declaration of Helsinki. Informed consent was obtained from each patient, and the study was approved by each institute's ethics committee.
Statistical methods
The main factors in the analysis were endoscopic and histological MH within 1 year. Analyses were aimed at searching for predictors of endoscopic and histological MH based on information collected at diagnosis, identifying predictors of MH, and investigating the association between MH after 1 year and outcomes of disease. Clinical demographics, blood markers and baseline endoscopic activity between patients who had and did not have endoscopic evaluation at 1 year were compared using the chi-square test for categorical variables, and independent t-tests for continuous variables. Medication was categorized into either having been prescribed or never been prescribed. Blood markers were coded into binomial expressions. Elevated ESR was defined as ≥ 20 mm/h in males and ≥ 30mm/h in females. Elevated CRP was defined as ≥ 10 mg/dl. Anaemia was defined as Hb level of ≤ 12 g/dl. Cohen's kappa coefficient was 0.704. Predictors of MH were assessed using univariate and multivariate logistic regression. Analysis was first performed with the exclusion of Mayo 1 and Nancy 1 at diagnosis, then their inclusion. Cumulative probabilities and 95% confidence intervals [CIs] were calculated using the Kaplan-Meier method. Impacts of MH on subsequent clinical course were compared using the chi-square test. Statistical analyses were performed using the SPSS statistical software package [SPSS] . A p value of less than 0.05 was considered statistically significant. Figure 2 ]. Among the 22 patients who had Mayo 1 at diagnosis, four had Mayo 2 at 1 year, and one had Mayo 3 at 1 year.
Results
Patient characteristics
Histological healing defined as a Nancy index of 0 or 1 was achieved in 35 [23.1%] patients; complete histological healing defined as a Nancy index of 0 was achieved in 11 [7.5%] patients. The cumulative probabilities of having ever achieved histological healing at 12, 18 and 24 months after diagnosis were 13.4, 31.4 and 68.1%, respectively [ Figure 2 ].
Predictors of endoscopic MH
On univariate analysis [ 
Predictors of histological healing
Discussion
To the best of our knowledge, this represents the first multicentre population-based study in Asia to assess the rate MH in UC patients, the predictors of MH and their impact on clinical outcomes. We showed that endoscopic MH was achieved in fewer than half [38.2%] of the patients in their first year of diagnosis. The figure was lower compared with the results of the only other published inception cohort study from the IBSEN study, which reported that endoscopic MH was achieved in 50% of UC patients. 4 There is no consistent definition of MH in the current literature-either Mayo 0 or Mayo 0 and 1 has been used to define MH. 16 In our study, we have defined MH as Mayo 0 or 1. In our statistical analysis, we have attempted to look for predictors of complete MH [Mayo 0], and found none. One possible reason was that very few patients achieved Mayo 0, and thus the study may be underpowered for outcome analysis.
We performed analysis first with the exclusion of Mayo 1 or Nancy 1 at diagnosis, then with its inclusion for comparison. Patients with baseline Mayo 1 were included since having a Mayo score of 1 at diagnosis was not necessarily predictive of having MH at 1 year. In fact, among the 22 patients who had Mayo 1 at diagnosis, four had Mayo 2 and one had Mayo 3 at 1 year. We also performed analysis excluding patients with Mayo 1 at baseline, and found that the proportion of patients achieving endoscopic MH was lower.
Similarly, we have included all subjects regardless of their baseline Nancy score findings. Among the three patients who had Nancy 1 at diagnosis, one had Nancy 2 and one had Nancy 4 at 1 year. When patients with Nancy 1 at baseline were excluded, the proportion of patients achieving histological MH was also lower.
Histology may detect more severe disease than endoscopy. 17 Patients with clinically and endoscopically inactive disease may still have histological inflammation. 18 We found that histological MH was achieved in fewer than one-third [23.1%] of the patients in their first year of diagnosis. There have so far been no other studies that have examined histological MH using a population-based cohort. The small proportion of patients showing either endoscopic or histological MH could suggest that more aggressive therapy may be warranted to improve long-term clinical outcomes in newly diagnosed UC patients.
We compared patients who had assessment of MH in the first year with those who did not. Compared with those who did not have assessment of MH in the first year of diagnosis, significantly more patients who had assessment of MH had elevated ESR, and were treated with corticosteroids or immunomodulators at baseline. This difference could be explained by the fact that patients with milder disease at diagnosis, with lower ESR levels and less likely to be treated with steroids or immunomodulators may be less likely to be followed up within 1 year or undergo repeated endoscopy assessment. Since patients with milder disease at diagnosis may have been excluded from the study, the proportion of patients achieving MH in the first year may be underestimated.
We found that elevated ESR at diagnosis was a predictor of endoscopic MH, which may suggest that a greater inflammatory activity at diagnosis is prognostic of poorer long-term clinical course in UC patients. However, this warrants further studies to investigate its role in predicting endoscopic MH. Limited data were available on MH in newly diagnosed UC patients. The IBSEN group identified that education longer than 12 years and extensive disease at diagnosis were significant predictors of endoscopic MH. 4 In our study, extensive disease at diagnosis was marginally significant [p = 0.063] as a negative predictor for histological MH on univariate analysis, and the effect became non-significant when multivariate analysis was performed. Data on endoscopic activity at diagnosis and ESR levels were not collected in the IBSEN study.
In UC patients in clinical remission, one study found that a longer duration of clinical remission, mild or moderate mucosal inflammation, and immunosuppressant use were associated with MH, with MH being defined as a Mayo score of 0. 19 Another study used a Mayo score > 1 as the outcome to investigate endoscopic inflammation in UC patients in clinical remission, and found that a shorter duration of clinical remission, higher white blood cell count and higher CRP levels were predictors of endoscopic inflammation. 20 In a study that investigated MH in IBD patients treated with anti-tumour necrosis factor antibodies, MH was defined as a Mayo score of 0 in UC, and Simple Endoscopic Score for Crohn's Disease (SES-CD) score of 0 in CD. They found that low CRP levels were a predictor for MH. 21 These studies implicated endoscopic activity and blood markers as potential predictors of MH. However, their roles in MH in newly diagnosed UC patients remain unclear. It has been shown that endoscopic MH consistently predicted favourable outcomes, including sustained clinical remission, reduced rates of hospitalization and fewer surgical resections. [1] [2] [3] [4] [5] Similarly, it has been shown that histological MH is associated with lower relapse rates and cancer risk. 18, 22, 23 However, the prognostic value of histological remission as a treatment target in IBD remains to be elucidated. 24 Until recently, this was due, in part, to the lack of a validated index for the assessment of histological disease activity in UC. The Nancy histological index was developed and validated in 2015. 15 In our study, we found that histological MH was achieved in fewer than one-third [23.1%] of patients. Predictors of histological healing were histological features of ulceration, and being an exsmoker at diagnosis.
We found that patients who have achieved either endoscopic or histological MH required less steroid use and fewer hospitalizations than those who did not. However, since the follow-up duration was relatively short, few patients demonstrated longer-term outcomes, including need for surgery, development of cancer and mortality. We found that among the five patients who had undergone surgery, none of them achieved endoscopic or histological MH within 1 year. Two patients developed cancer, one of whom achieved endoscopic MH but not histological MH; the other did not achieve either endoscopic or histological MH. Longer follow up of this cohort of patients would be needed to determine the impacts of MH on these outcomes.
The major strength of this study is the inclusion of a populationbased cohort across a large but well-defined geographical area in Asia, with the use of strict and uniform diagnostic criteria and inclusion of patients from inception. In addition, it is the first epidemiology study in Asia to investigate both endoscopic and histological MH in newly diagnosed UC patients, using a validated endoscopic and histological score, respectively. This study has several limitations. First, the cohort consisted of patients from different countries but represented mostly Chinese patients. As healthcare systems were heterogeneous, choice of medication and surgical therapy differed. Subgroup analysis stratified by ethnicity or medications was not performed. Second, clinical activities were assessed using the Simple Clinical Colitis Activity Index, rather than clinical subscore of Mayo. Third, retrospective scoring of mucosal inflammation based on colonoscopy and histology reports can be associated with bias. Nonetheless, two independent researchers were involved in the scoring of endoscopic and histological activity, and the inter-rater agreement was good. All centres were also known to have high-quality endoscopic and recording systems, with colonoscopies being performed by experienced endoscopists or IBD experts. Fourth, the date of assessment of MH was variable due to differences in clinical practices between countries for endoscopic reassessments, and could affect the proportion of patients achieving MH. In particular, in patients who underwent endoscopy months after diagnosis, the absence of MH could be attributed to relapse of disease after initial response.
In conclusion, this prospective population-based study showed that endoscopic MH and histological MH were achieved in fewer than half and fewer than one-third of patients with newly diagnosed UC, respectively, within the first year of diagnosis. An elevated ESR was an independent negative predictor of endoscopic MH; histological features of ulceration and being an ex-smoker at diagnosis were independent negative predictors of histological MH. Either endoscopic of histological MH was associated with less steroids use and fewer hospitalizations.
